🇺🇸 FDA
Pipeline program

CGT4859

CGT4859-24-101

Phase 2 small_molecule active

Quick answer

CGT4859 for Intrahepatic Cholangiocarcinoma (Icc) is a Phase 2 program (small_molecule) at Cogent Biosciences with 1 ClinicalTrials.gov record(s).

Program details

Company
Cogent Biosciences
Indication
Intrahepatic Cholangiocarcinoma (Icc)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials